Enanta Pharmaceuticals, Inc. (ENTA) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $12.59 (-3.12%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Oct 1, 2025 | Akash Tewari | Jefferies | $20.00 | +58.9% |
| Jun 3, 2025 | Roy Buchanan | JMP Securities | $24.00 | +90.7% |
| Jul 29, 2022 | Yasmeen Rahimi | Piper Sandler | $87.00 | +591.3% |
Top Analysts Covering ENTA
ENTA vs Sector & Market
| Metric | ENTA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | +57.4% | +16366.1% | +18.0% |
| P/E Ratio | -4.10 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $13M | $15M | $16M | 2 |
| 2026-12-31 | $13M | $14M | $15M | 3 |
| 2027-03-31 | $12M | $13M | $14M | 3 |
| 2027-06-30 | $11M | $13M | $14M | 2 |
| 2027-09-30 | $11M | $13M | $13M | 2 |
| 2028-09-30 | $58M | $65M | $71M | 4 |
| 2029-09-30 | $61M | $68M | $75M | 2 |
| 2030-09-30 | $51M | $57M | $63M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.74 | $-0.68 | $-0.57 | 1 |
| 2026-12-31 | $-0.51 | $-0.47 | $-0.40 | 2 |
| 2027-03-31 | $-0.55 | $-0.51 | $-0.43 | 2 |
| 2027-06-30 | $-0.55 | $-0.51 | $-0.43 | 1 |
| 2027-09-30 | $-0.56 | $-0.52 | $-0.44 | 1 |
| 2028-09-30 | $-4.11 | $-2.18 | $-1.39 | 4 |
| 2029-09-30 | $-1.83 | $-1.63 | $-1.40 | 1 |
| 2030-09-30 | $-2.47 | $-2.19 | $-1.88 | 1 |
Frequently Asked Questions
What is the analyst consensus for ENTA?
The consensus among 1 analysts covering Enanta Pharmaceuticals, Inc. (ENTA) is Buy with an average price target of $48.20.
What is the highest price target for ENTA?
The highest price target for ENTA is $87.00, set by Yasmeen Rahimi at Piper Sandler on 2022-07-29.
What is the lowest price target for ENTA?
The lowest price target for ENTA is $20.00, set by Akash Tewari at Jefferies on 2025-10-01.
How many analysts cover ENTA?
1 analysts have issued ratings for Enanta Pharmaceuticals, Inc. in the past 12 months.
Is ENTA a buy or sell right now?
Based on 1 analyst ratings, ENTA has a consensus rating of Buy (2.00/5) with a +57.4% upside to the consensus target of $48.20.
What are the earnings estimates for ENTA?
Analysts estimate ENTA will report EPS of $-0.68 for the period ending 2026-09-30, with revenue estimated at $15M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.